Alkem Laboratories accepts resignation of Dr. Jitendra Singh Huda

1 min read     Updated on 23 Jul 2026, 01:34 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Alkem Laboratories Limited has accepted the resignation of Dr. Jitendra Singh Huda, Senior Vice President, effective July 23, 2026. The resignation was submitted to pursue professional opportunities. The company confirmed the cessation of his senior management duties on the said date.

powered bylight_fuzz_icon
46339475

*this image is generated using AI for illustrative purposes only.

Alkem Laboratories Limited has accepted the resignation of Dr. Jitendra Singh Huda from the position of Senior Vice President, effective July 23, 2026. The company disclosed that the resignation was tendered to pursue professional opportunities. Consequently, Dr. Huda will cease to hold his senior management position within the organization starting from the stated date.

The resignation was communicated via email on July 14, 2026, and formally accepted by Dr. Rajorshi Ganguli, President and Global HR Head, on July 15, 2026. In his resignation email, Dr. Huda cited professional growth as the reason for stepping down and confirmed his availability until the end of July 23, 2026, to complete pending responsibilities.

Regulatory Disclosure

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Divya Mewani, Vice President – Legal & Deputy Company Secretary.

The company acknowledged the valuable contributions made by Dr. Huda during his tenure as Senior Management Personnel. The specific details regarding the change in senior management were provided in Annexure I to the regulatory filing.

Key Details of Resignation

Particulars Details
Reason for change Resignation
Date of cessation July 23, 2026
Brief profile Not Applicable
Disclosure of relationships Not Applicable

Historical Stock Returns for Alkem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+0.15%-1.16%+4.22%-2.87%+12.50%+66.07%

Who will be appointed to replace Dr. Jitendra Singh Huda, and how will this transition impact Alkem's strategic direction?

What specific professional opportunities is Dr. Huda pursuing, and could this indicate a trend of talent movement within the pharmaceutical industry?

How will Alkem Laboratories ensure continuity in the responsibilities previously handled by Dr. Huda during the transition period?

Alkem Laboratories completes acquisition of 51-55% stake in Occlutech Holding AG

1 min read     Updated on 17 Jul 2026, 07:11 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Alkem Laboratories announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has completed the acquisition of at least 51% and up to 55% of the total issued equity share capital of Occlutech Holding AG, a company incorporated in Switzerland. Consequently, Occlutech has become a step-down subsidiary of Alkem Laboratories. The acquisition was funded by a previous capital infusion where Alkem Laboratories acquired shares in Alkem Medtech for ₹1,100 crore via a rights issue at ₹13.86 per share.

powered bylight_fuzz_icon
45830023

*this image is generated using AI for illustrative purposes only.

Alkem Laboratories has completed the acquisition of a 51-55% stake in Swiss medical device manufacturer Occlutech Holding AG through its wholly owned subsidiary, Alkem Medtech Private Limited. The transaction, executed pursuant to a Share Purchase Agreement, results in Occlutech becoming a step-down subsidiary of Alkem Laboratories. The disclosure was submitted to the stock exchanges under Regulation 30 of the SEBI LODR Regulations.

To facilitate this acquisition, Alkem Laboratories had previously infused capital into Alkem Medtech. This involved the acquisition of 79,36,50,794 equity shares for a total cash consideration of ₹1,100 crore via a rights issue at an allotment price of ₹13.86 per share. The shares were allotted on July 15, 2026.

Financial Details of the Transaction

The following table outlines the key financial metrics related to the capital infusion for the acquisition:

Particulars Details
Total shares acquired in Alkem Medtech 79,36,50,794 equity shares
Issue price per share ₹13.86
Total consideration ₹1,100 crore
Mode of payment Cash consideration
Date of allotment July 15, 2026

Background of Alkem Medtech

Alkem Medtech is a wholly owned subsidiary of Alkem Laboratories in India. Incorporated on March 27, 2024, the entity operates in the medical device sector with a focus on cardiovascular and orthopedic fields. For the financial year ended March 31, 2026, Alkem Medtech reported a turnover of ₹15.13 crore, compared to nil in the previous financial year. The subsidiary is strategically positioned to support the company's expansion into the medical device segment.

Historical Stock Returns for Alkem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+0.15%-1.16%+4.22%-2.87%+12.50%+66.07%

How does Alkem Laboratories plan to integrate Occlutech’s product portfolio into its existing Indian market operations?

What are the projected revenue synergies and cost savings expected from this acquisition over the next fiscal year?

Will Alkem Medtech pursue further acquisitions or partnerships to expand its cardiovascular and orthopedic device verticals?

More News on Alkem Laboratories

1 Year Returns:+12.50%